Table 5.

Outcomes versus treatment in 30 crystalline LCPT patients

CharacteristicSCT+Chemotherapy (n=10)Chemotherapy Alone (n=12)None (n=8)P Value
Median age (range), yr51 (39–59)67.5 (47–85)65 (47–87)0.001
SCT versus chemotherapy 0.002
SCT versus none 0.003
Chemotherapy versus none 0.79
MM6310.05
SCT versus chemotherapy 0.07
SCT versus none 0.07
Chemotherapy versus none >.99
Smoldering MM1140.06
MGRS3630.65
Other HLN0200.10
eGFR (initial)a48.8 (49.8)30.0 (32.0)34.8 (37.9)0.19
SCT versus chemotherapy 0.09
SCT versus none 0.25
Chemotherapy versus none 0.52
sCr, mg/dl (initial)a2.01 (1.55)2.48 (2.15)2.38 (1.85)0.48
Proteinuria (initial), g/24 ha3.05 (1.41)2.95 (2.95)2.15 (1.89)0.01
SCT versus chemotherapy 0.01
SCT versus none >.99
Chemotherapy versus none 0.03
Follow-up monthsa65.2 (57.5)40.5 (32.0)59.0 (48.5)0.60
eGFR (final)ab58.9 (51.5)31.0 (27.8)27.9 (33.5)0.01
SCT versus chemotherapy 0.01
SCT versus none 0.01
Chemotherapy versus none 0.94
eGFR<60 (final)ab7/1012/127/70.32
Change in eGFR+10.1 (+7.6)+1.0 (-4.5)−6.9 (-4.9)0.04
SCT versus chemotherapy 0.16
SCT versus none 0.06
Chemotherapy versus none 0.57
sCr (final), mg/dlab1.43 (1.45)2.27 (2.07)3.11 (1.75)0.05
SCT versus chemotherapy 0.03
SCT versus none 0.07
Chemotherapy versus none 0.87
Proteinuria (final), g/24 hab0.85 (0.80)1.56 (1.59)1.96 (1.92)0.05
SCT versus chemotherapy 0.15
SCT versus none 0.02
Chemotherapy versus none 0.39
Hematologic outcomes0.12
 CR2/103/120/80.39
 VGPR1/100/120/80.62
 PR2/100/121/80.35
 Stable disease5/109/127/80.24
Renal functional outcomesbc0.07
SCT versus chemotherapy 0.16
SCT versus none 0.12
Chemotherapy versus none 0.66
 Improved4/103/121/7
 Stable6/105/124/7
 Worsening CKD0/104/120/7
 ESRD0/100/122/7
Death0/104/123/80.12
  • SCr, serum creatinine.

  • a Values are mean (median).

  • b One untreated patient had no renal follow-up data.

  • c Improved: ΔSCr>–0.5 mg/dl; stable: ΔSCr±0.5 mg/dl from baseline; worsening: ΔSCr>0.5 mg/dl.